International Journal of
Reproductive Biomedicine
Thu, Apr 25, 2024
[Archive]
Volume 13, Issue 6 (8-2015)
IJRM 2015, 13(6): 337-344 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
He B, Junping C, Li H, Weihong T, Lintao X, Shikai W. Effects of human menopausal gonadotropin on zona pellucida and pregnancy outcomes of ovarian stimulation protocols. IJRM 2015; 13 (6) :337-344
URL: http://ijrm.ir/article-1-655-en.html
URL: http://ijrm.ir/article-1-655-en.html
1- People’s Hospital of Guangxi Autonomous Region, Nanning, 530021, China
2- People’s Hospital of Guangxi Autonomous Region, Nanning, 530021, China , chengjunpingyy@163.com
2- People’s Hospital of Guangxi Autonomous Region, Nanning, 530021, China , chengjunpingyy@163.com
Abstract: (3123 Views)
Background: Human menopausal gonadotropin (hMG) has contributed many improvements to human assisted reproduction. However, effects of hMG on oocyte development and clinical results remain controversial.
Objective: This study was conducted to investigate the effects of hMG on the zona pellucida of oocytes, as well as clinical results in superovulation treatment.
Materials and Methods: This retrospective study was performed with 150 cycles of long-protocol treatment using recombinant follicle-stimulating hormone (r-FSH) with or without hMG. The number of retrieved oocytes, fertilization rate, implantation rate, pregnancy rate, and birefringence and thickness of the zona pellucida of oocytes were investigated.
Results: No significant differences were existed in r-FSH +hMG, and r-FSH groups in the number of retrieved oocytes (11.99±0.75 vs. 13.9±0.73, p=0.06), maturation rate (84.76% vs. 83.32%, p=0.42), pregnancy rate (37.31% vs. 37.66%, p=0.96), and embryo implantation rate (28.97% vs. 23.26%, p=0.30). However, fertilization rate (82.95% vs. 78.75%; p=0.02) was different. Zona pellucida birefringence was lower in the r-FSH +hMG group than in the r-FSH group (6.70±0.50 vs. 7.04±0.31; p=0.53). Thickness values of the metaphase-II zona pellucida of the r-FSH +hMG group on the first (19.20±0.14 vs. 18.75±0.10; p=0.01) and second (18.69±0.12 vs. 18.17±0.14; p=0.00) days of insemination were both higher than those of the r-FSH group.
Conclusion: hMG positively influenced the improvement of oocyte fertilization, as well as the birefringence and thickness of zona pellucida.
Objective: This study was conducted to investigate the effects of hMG on the zona pellucida of oocytes, as well as clinical results in superovulation treatment.
Materials and Methods: This retrospective study was performed with 150 cycles of long-protocol treatment using recombinant follicle-stimulating hormone (r-FSH) with or without hMG. The number of retrieved oocytes, fertilization rate, implantation rate, pregnancy rate, and birefringence and thickness of the zona pellucida of oocytes were investigated.
Results: No significant differences were existed in r-FSH +hMG, and r-FSH groups in the number of retrieved oocytes (11.99±0.75 vs. 13.9±0.73, p=0.06), maturation rate (84.76% vs. 83.32%, p=0.42), pregnancy rate (37.31% vs. 37.66%, p=0.96), and embryo implantation rate (28.97% vs. 23.26%, p=0.30). However, fertilization rate (82.95% vs. 78.75%; p=0.02) was different. Zona pellucida birefringence was lower in the r-FSH +hMG group than in the r-FSH group (6.70±0.50 vs. 7.04±0.31; p=0.53). Thickness values of the metaphase-II zona pellucida of the r-FSH +hMG group on the first (19.20±0.14 vs. 18.75±0.10; p=0.01) and second (18.69±0.12 vs. 18.17±0.14; p=0.00) days of insemination were both higher than those of the r-FSH group.
Conclusion: hMG positively influenced the improvement of oocyte fertilization, as well as the birefringence and thickness of zona pellucida.
Type of Study: Original Article |
References
1. Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011; 95: 1031-1036. [DOI:10.1016/j.fertnstert.2010.10.021]
2. Barrenetxea G, Agirregoikoa JA, Jiménez MR, de Larruzea AL, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril 2008; 89: 546-555. [DOI:10.1016/j.fertnstert.2007.03.088]
3. Griesinger G, Shapiro DB, Kolibianakis EM, Witjes H, Mannaerts BM. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. Reprod Biomed Online 2011; 23: 457-465. [DOI:10.1016/j.rbmo.2011.06.016]
4. Wong PC, Qiao J, Ho C, Ramaraju GA, Wiweko B, Takehara Y, et al. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online 2011; 23: 81-90. [DOI:10.1016/j.rbmo.2011.03.023]
5. Berkkanoglu M, Isikoglu M, Nurse DA, Ozgur K. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertil Steril 2007; 88: 665-669. [DOI:10.1016/j.fertnstert.2006.11.150]
6. Gordon UD, Harrison RF, Fawzy M, Hennelly B, Gordon AC. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril 2001; 75: 324-331. [DOI:10.1016/S0015-0282(00)01701-5]
7. Ferraretti AP, Gianaroli L, Magli MC, D'angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004; 82: 1521-1526. [DOI:10.1016/j.fertnstert.2004.06.041]
8. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012; 97: 1108-1114. [DOI:10.1016/j.fertnstert.2012.01.130]
9. Feigenberg T, Simon A, Ben-Meir A, Gielchinsky Y, Laufer N. Role of androgens in the treatment of patients with low ovarian response. Reprod BioMed Online 2009; 19: 888-898. [DOI:10.1016/j.rbmo.2009.09.012]
10. Coppola F, Port ER, Barusi L, Ferrari B, Salvarani MC, Vadora E. Profound luteinizing hormone suppression induces a deleterious follicular environment during assisted reproduction technology. Fertil Steril 2003; 79: 459-460. [DOI:10.1016/S0015-0282(02)04671-X]
11. Propst AM, Hill MJ, Bates GW, Palumbo M, Van Horne AK, Retzloff MG. Low-dose human chorionic gonadotropin may improve in-vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril 2011; 96: 898-904. [DOI:10.1016/j.fertnstert.2011.06.069]
12. Sönmezer M, Duvan CI, Özmen B, Taşçi T, Ozkavukçu S, Atabekoğlu CS. Outcomes after early or midfollicular phase LH supplementation in previous inadequate responders. Reprod BioMed Online 2010; 20: 350-357. [DOI:10.1016/j.rbmo.2009.11.022]
13. Van Horne AK, Bates GW Jr, Robinson RD, Arthur NJ, Propst AM. Recombinant follicle-stimulating hormone (rFSH) supplemented with low-dose human chorionic gonadotropin compared with rFSH alone for ovarian stimulation for in vitro fertilization. Fertil Steril 2007; 88: 1010-1013. [DOI:10.1016/j.fertnstert.2006.12.051]
14. Ferrari B, Barusi L, Coppola F. Clinical and Endocrine Effects of Ovulation Induction with FSH and hCG Supplementation in Low Responders in the Midfollicular Phase: A Pilot Study. J Reprod Med 2002; 47: 137-143.
15. Cheng JP, He B, Huang L, Tan WH, Xue LT, Wang SK, et al. Effect of Different Infertility Etiologies on Zona Pellucida, Embryo Development and Pregnancy Outcome. Reprod Contracept 2011; 31: 347-353.
16. Cheng JP, He B, Huang L, Lu F, Wang X, Wu Z, et al. Quantitative analysis of the intensity of zona pellucida birefringence of oocytes during IVF cycles. Reprod Fertil Dev 2010; 22: 1167-1174. [DOI:10.1071/RD10047]
17. Rose RD, Gilchrist RB, Kelly JM, Thompson JG, Sutton-McDowall ML. Regulation of sheep oocyte maturation using cAMP modulators. Theriogenology 2013; 79: 142-148. [DOI:10.1016/j.theriogenology.2012.09.020]
18. Tsuji T, Kiyosu C, Akiyama K, Kunieda T. CNP/NPR2 signaling maintains oocyte meiotic arrest in early antral follicles and is suppressed by EGFR-mediated signaling in preovulatory follicles. Mol Reprod Dev 2012; 366: 308-316. [DOI:10.1002/mrd.22114]
19. Baruffi RLR, Mauri AL, Petersen CG, Felipe V, Martins AM, Cornicelli J, et al. Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reprod Biomed Online 2007; 14: 14-25. [DOI:10.1016/S1472-6483(10)60758-4]
20. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril 2007; 87: 542-546. [DOI:10.1016/j.fertnstert.2006.06.059]
21. Balasch J, Fabregues F. Pregnancy after administration of high dose recombinant human LH alone to support final stages of follicular maturation in a woman with long-standing hypogonadotrophic hypogonadism. Reprod BioMed Online 2003; 6: 427-431. [DOI:10.1016/S1472-6483(10)62162-1]
22. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH ceiling effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003; 18: 314. [DOI:10.1093/humrep/deg066]
23. Fábregues F, Creus M, Pe arrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril 2006; 85: 925-931. [DOI:10.1016/j.fertnstert.2005.09.049]
24. De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary down regulation. Clin Endocrinol 2004; 60: 637-643. [DOI:10.1111/j.1365-2265.2004.02027.x]
25. Host E, Gabrielsen A, Lindenberg S, Smidt-Jensen S. Apoptosis in human cumulus cells in relation to zona pellucida thickness variation, maturation stage, and cleavage of the corresponding oocyte after intracytoplasmic sperm injection. Fertil Steril 2002; 77: 511-515. [DOI:10.1016/S0015-0282(01)03006-0]
26. Filicori M, Cognigni GE. Roles and novel regimens of luteinizing hormone and follicle-stimulating hormone in ovulation induction. J Clin Endocrinol Metab 2001; 86: 1437-1441.
27. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000; 15: 1003-1008. [DOI:10.1093/humrep/15.5.1003]
28. Weghofer A, Munne S, Brannath W, Chen S, Tomkin G, Cekleniak N, et al. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Hum Reprod 2008; 23: 499-503. [DOI:10.1093/humrep/dem412]
29. Lossl K, Andersen AN, Loft A, Freiesleben NL, Bangsbøll S, Andersen CY. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod 2006; 21: 2593-2600. [DOI:10.1093/humrep/del221]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
